Department of Medicine, University of California Irvine Medical Center, Orange, CA, USA.
Department of Dermatology, University of California - San Diego, La Jolla, CA, USA.
J Oncol Pharm Pract. 2023 Oct;29(7):1789-1792. doi: 10.1177/10781552231185505. Epub 2023 Jul 4.
Enfortumab vedotin is an antibody drug conjugate approved for management of pretreated locally advanced or metastatic urothelial carcinoma, which is associated with a rare risk of drug extravasation and soft tissue reactions.
We report two cases of EV extravasation with subsequent development of bullae and cellulitis.
They were both treated for cellulitis and had conservative management without surgical intervention and were able to resume treatment with Enfortumab vedotin without subsequent adverse events.
We propose that EV acts as a vesicant upon extravasation, highlight measures to prevent extravasation events, and encourage appropriate measures when dealing such as attempt of aspiration, removal of catheter, application of compresses, and thorough documentation with photographic evidence.
依维莫司丁是一种抗体药物偶联物，已被批准用于治疗预处理的局部晚期或转移性尿路上皮癌，该药存在药物外渗和软组织反应的罕见风险。
我们报告了两例依维莫司丁外渗的病例，随后出现水疱和蜂窝织炎。
这两例均接受了蜂窝织炎治疗，未进行手术干预，采用保守治疗，随后能够继续接受依维莫司丁治疗，无后续不良事件发生。
我们认为依维莫司丁外渗时具有刺激性，强调了预防外渗事件的措施，并鼓励在处理此类事件时采取适当的措施，如尝试抽吸、拔出导管、使用敷布、彻底记录并附有照片证据。
